title: Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta-analysis of randomized controlled studies with 12-month follow-up.
abstract: BACKGROUND
  Whether patients with functional dyspepsia (FD) should receive Helicobacter pylori eradication therapy remains controversial.
  
  
  OBJECTIVE
  This meta-analysis was to evaluate the long-term effects of H. pylori eradication on dyspeptic symptoms of patients with FD, by selecting the most recent well-designed randomized controlled trials.
  
  
  METHODS
  English-language articles in the medical literature containing information on the long-term (≥ 12 mo) effects of H. pylori eradication on dyspeptic symptoms in patients with FD were identified by searching the Medline, PubMed, and EMBASE databases. The MeSH and/or keywords included Helicobacter pylori OR H. pylori OR HP; functional dyspepsia OR non-ulcer dyspepsia; eradication OR cure or treatment; and improvement OR resolution. The Review Manager 4.2.2 was used for the meta-analysis.
  
  
  RESULTS
  Fourteen randomized controlled studies were included in the meta-analysis. Improvements of dyspepsia symptoms in patients of eradication group were significantly better than in patients of the control group [odds ratio (OR), 1.38; 95% confidence interval (CI), 1.18-1.62] (Z=4.00, P<0.0001) at the end of the follow-up period with low heterogeneity (I=51.8%, P=0.01). In a subgroup analysis on geographical regions, improvements of dyspepsia symptoms in patients of eradication group were all significantly better than in patients of control group in the European (OR, 1.49; 95% CI, 1.10-2.02), Asian (OR, 1.54; 95% CI, 1.07-2.21), and American populations (OR, 1.43; 95% CI, 1.12-1.83).
  
  
  CONCLUSIONS
  H. pylori eradication therapy is associated with improvement of dyspeptic symptoms in patients with FD, which is consistently demonstrated in the Asian, European, and American populations.
authors.affiliation: *Department of Gastroenterology, Shengze Hospital of Nanjing Medical University, Wujiang, Jiangsu †Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Zhao
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Wen-Fang
authors.initials: WF
authors.lastname: Cheng
authors.forename: Wei-Jia
authors.initials: WJ
authors.lastname: Shi
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Xiao-Lin
authors.initials: XL
authors.lastname: Pan
authors.forename: Guo-Xin
authors.initials: GX
authors.lastname: Zhang
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D044466:Asian People; D016009:Chi-Square Distribution; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology / Q000382:microbiology; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D044465:White People
chemical_list: D000900:Anti-Bacterial Agents